This report was first published by Endpoints News. To see the original version, click here
Eli Lilly had very little competition in its eventual deal for Ventyx Biosciences, one of the leading drug developers in the hot NLRP3 arena.
The Indianapolis drug giant scooped up the San Diego biotech for $1.2 billion after months of due diligence and a few rounds of price negotiations, according to a new regulatory document outlining how the deal was hashed out.
您已阅读17%（456字），剩余83%（2150字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。